LMO7-ALK fusion
|
NSCLC
|
LMO7-ALK fusion
|
NSCLC
|
alectinib Resistant: C3 – Early Trials
|
alectinib Resistant: C3 – Early Trials
|
LMO7-ALK fusion
|
NSCLC
|
LMO7-ALK fusion
|
NSCLC
|
crizotinib + ensartinib Sensitive: C3 – Early Trials
|
crizotinib + ensartinib Sensitive: C3 – Early Trials
|